Optimizing Management Approaches in Patients with Moderate-to-Severe Atopic Dermatitis


Optimizing Management Approaches in Patients with Moderate-to-Severe Atopic Dermatitis

Topic: Allergy/ Immunology
Relevant Terms: Atopic Dermatitis (AD)
Primary Audience: Dermatology clinicians who manage patients with moderate-to-severe atopic dermatitis (AD)
Launch Date: 27-Mar-18
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: 27-Mar-19
Curriculum Name: The Learning Pathway in Atopic Dermatitis: Optimizing Management Approaches in Patients with...

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with atopic dermatitis that reflect evidence-based guidelines, use of new therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Address quality-of-life issues and psychosocial comorbidities in managing patients with atopic dermatitis
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes


    Mark Lebwohl, MD (Chair)
    Kimberly and Eric J. Waldman Professor of Dermatology
    Icahn School of Medicine at Mount Sinai
    Chairman, Kimberly and Eric J. Waldman Department of Dermatology
    Mount Sinai Health System
    New York, NY
    Emma Guttman, MD, PhD 
    Professor of Dermatology, Sol and Clara Kest 
    Icahn School of Medicine at Mount Sinai 
    New York, NY
    David M. Pariser, MD, FACP, FAAD
    Professor of Dermatology
    Eastern Virginia Medical School
    Virginia Clinical Research
    Pariser Dermatology Specialists
    Norfolk, VA
    Joint Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • Mark Lebwohl, MD, is an employee of Mount Sinai which receives research funds from: Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer, Valeant, and ViDac; Allergan, Aqua Leo-pharma, and Promius (Consultant)
    • Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Eli Lilly, Escalier,  Galderma, Glenmark, Kiowa Kirin, Kymab, LEO Pharmaceuticals, Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Theravance, and Vitae (Consultant)
    • David M. Pariser, MD, FACP, FAAD, has affiliations with Bickel Biotechnology, Biofrontera AG, Celegene, Dermira, DUSA Pharmaceuticals, LEO Pharmaceuticals, Novartis, Promius, Regeneron, Sanofi, TheraVida, and Valeant (Consultant); Pfizer (Advisory Board); Abbott Laboratories, Amgen, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant Sciences, Eli Lilly, LEO Pharmaceuticals, Merck, Novartis, Novo Nordisk, Ortho Dermatologics, Peplin, Photocure, Promius, Regeneron, Stiefel, and Valeant (Contracted Research).  
    RMEI Medical Education, LLC
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
    • Misha Mutizwa, MD, has affiliations with Celgene (Consulting Fees).
    • Sharon Powell, has no affiliations with commercial interests to disclose.       
    Postgraduate Institute for Medicine
    The following PIM planners and managers: Judi Smelker-Mitchek, MBA, MSN, RN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Estimated time to complete: 0.75 hour
    Medium: Internet
    There is no fee for this educational activity.
    This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
    By reviewing the course content and successfully completing the post-test and evaluation, physicians/DOs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.
    Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.